‣ Xtandi with IO combo- please refer chapter no. 7
5. Zytiga + ARN-509- How big is it has potential to change the treatment paradigm of Prostate Cancer? A competitive threat post Zytiga patent expiry for Xtandi?
‣ Zytiga generic entry: An opportunity for ARN-509 or A threat for JNJ?
‣ Zytiga patent Expiry- more worries for early entry in US market than Ex-US
‣ Use patents of Zytiga: the 438 Patent
‣ Ongoing clinical trial of Zytiga with ARN-509
‣ Ongoing clinical trials of Zytiga with Xtandi
‣ New formulation under development for Zytiga / Xtandi
‣ Combination studies of Zytiga with other targeted therapy vs. combination study of Xtandi with other targeted therapies, Ongoing Clinical trials
‣ Combination of Zytiga with Onapristone
Browse All Reports of This Category at: https:// marketreportscenter. com / reports / category / life-sciences
6. Pipeline Antiandrogens: Androgen Receptor Inhibitors vs. Androgen Synthesis inhibitors-
‣ Androgen Receptor inhibitors: Who could be the major threat to Xtandi?
� ARN-509- A better Xtandi is in making o Ongoing Clinical trials of ARN-509 and our expectations o ARN-509- Clinical data comparison vs. Xtandi and other pipeline candidates � ODM-201- Does its safety differentiate it against ARN-509 / Xtandi? �
�
ODM-201 and ODM-204 has potential to challenge current leader Xtandi and Zytiga
EPI-001 and EPI-506